ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

02 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

18 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

17 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

12 Nov 2025 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

10 Nov 2025 08:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

05 Nov 2025 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

04 Nov 2025 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

26 Aug 2025 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

12 Aug 2025 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

05 Aug 2025 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

28 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

15 Jul 2025 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

10 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

13 May 2025 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

07 May 2025 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

06 May 2025 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

02 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

27 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

26 Mar 2025 08:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

20 Mar 2025 16:00:00 By Nasdaq GlobeNewswire